Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: kathleen who wrote (414)	10/12/1998 11:34:00 AM
From: muddphudd	Read Replies (1) \| Respond to of 586

I recently asked Jim Jubak from Microsoft (and occasionally CNBC) about his impressions of Cypress. Here they are: "Sorry, I really don't follow Cypress Bioscience but I did read the company's most recent 10Q. Pretty clear from that that the company is rolling all its dice on this one product. They cut back on R&D, cut back on sales force, and actually lost sales on existing product to get sales force set to launch new one if they get approval in October. And of course they do note that they only have money to get to the end of the year. The stock is cheap but this is a one product company at the moment so the risk is real high too. I'd call it a crap shoot." I still believe that CYPB needs to sign a partner on board and penetrate the rheumatology market if this things is going to fly. Lets hope they are making progress. Any ideas as to when we will here of a partner? The first deadline came and went. Go CYPB!!!